Volume 28, No 4, Apr 2018

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 28 Issue 4, April 2018: 393-394

RESEARCH HIGHLIGHTS

SETD2 — linking stem cell survival and transformation

Mrinal M. Patnaik ¹ and Omar Abdel-Wahab ²

¹ Department of Internal Medicine, Mayo Clinic, Division of Hematology, Rochester, MN, USA and ²Human Oncology and Pathogenesis Program and Acute Leukemia Service,Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Correspondence: Omar Abdel-Wahab (abdelwao@mskcc.com)

SETD2encodes a histone H3 lysine 36 (H3K36) methyltransferase affected by mutations and deletions in a wide variety of cancers. WhetherSETD2loss alone can initiate tumorigenesis has not been established previously but in the present study, Zhang et al. identify that SETD2 deficiency eventually results in outgrowth of cells with a phenotype consistent with myelodysplastic syndromes and acute myeloid leukemia.

10.1038/s41422-018-0025-7

FULL TEXT | PDF

Browse 1200